Ruepp Stefan, Janovitz Evan, Brodie Thomas, White Randy, Santella Joseph, Hynes John, Carman Julie, Pan Duohai, Wu Yang, Hanumegowda Umesh, Gemzik Brian, Megill John, DiPiero Janet, Drexler Dieter, Su Ching-Chiang, Hageman Michael
Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
J Pharmacol Toxicol Methods. 2019 Mar-Apr;96:1-8. doi: 10.1016/j.vascn.2018.12.003. Epub 2018 Dec 13.
Low intrinsic solubility leading to poor oral bioavailability is a common challenge in drug discovery that can often be overcome by formulation strategies, however, it remains a potential limitation that can pose challenges for early risk assessment and represent a significant obstacle to drug development. We identified a selective inhibitor (BMS-986126) of the IL-1 receptor-associated kinase 4 (IRAK4) with favorable properties as a lead candidate, but with unusually low intrinsic solubility of <1 μg/mL.
Conventional histopathology identified the issue of crystal formation in vivo. Subsequent investigative work included confocal Raman micro-spectroscopy, MALDI-MS, polarized light microscopy of fresh wet-mount tissue scrapings and transmission electron microscopy.
BMS-986126 was advanced into a 2-week toxicology study in rats. The main finding in this study was minimal granulomatous inflammation in the duodenum, associated with the presence of birefringent crystals at the highest dosage of 100 mg/kg/day. Considering the safety margin, and the single location of the lesion, BMS-986126 was further progressed into IND-enabling toxicology studies where tolerability deteriorated with increasing dosing duration. Birefringent crystals and granulomatous inflammation were detected in multiple organs at dosages ≥20 mg/kg/day. Raman spectroscopy confirmed the identity of the crystals as BMS-986126. Therefore, follow up investigations were conducted to further characterize drug crystallization and to evaluate detection methods for their potential to reliably detect in vivo crystallization early.
The purpose of our efforts was to identify critical factors influencing in vivo drug crystallization and to provide a preliminary assessment (based on one compound) which method would be best suited for identifying crystals. Results indicated a combination of methods was required to provide a complete assessment of drug crystallization and that a simple technique, scraping of freshly collected tissue followed by evaluation under polarizing light was suitable for detecting crystals. However, dosing for 2 weeks was required for crystals to grow to a clearly detectable size.
内在溶解度低导致口服生物利用度差是药物研发中常见的挑战,通常可通过制剂策略克服,但它仍是一个潜在限制,可能给早期风险评估带来挑战,并成为药物开发的重大障碍。我们鉴定出一种白细胞介素-1受体相关激酶4(IRAK4)的选择性抑制剂(BMS-986126),其性质良好,可作为主要候选药物,但内在溶解度异常低,<1μg/mL。
传统组织病理学确定了体内晶体形成问题。后续研究工作包括共聚焦拉曼显微光谱、基质辅助激光解吸电离质谱、新鲜湿装组织刮片的偏光显微镜检查和透射电子显微镜检查。
BMS-986126进入了大鼠为期2周的毒理学研究。该研究的主要发现是十二指肠出现轻微的肉芽肿性炎症,与最高剂量100mg/kg/天出现双折射晶体有关。考虑到安全边际以及病变的单一位置,BMS-986126进一步进入支持新药临床试验申请的毒理学研究,随着给药持续时间增加,耐受性恶化。在剂量≥20mg/kg/天的多个器官中检测到双折射晶体和肉芽肿性炎症。拉曼光谱证实晶体为BMS-986126。因此,开展了后续研究以进一步表征药物结晶,并评估检测方法可靠早期检测体内结晶的潜力。
我们工作的目的是确定影响体内药物结晶的关键因素,并提供初步评估(基于一种化合物)哪种方法最适合鉴定晶体。结果表明需要多种方法结合才能全面评估药物结晶,一种简单技术,即刮取新鲜采集的组织并在偏光下评估,适用于检测晶体。然而,晶体需要2周的给药时间才能生长到可清晰检测的大小。